Compare ICCM & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICCM | XRTX |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.9M |
| IPO Year | 2013 | 2018 |
| Metric | ICCM | XRTX |
|---|---|---|
| Price | $0.72 | $1.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $22.67 | N/A |
| AVG Volume (30 Days) | ★ 110.0K | 36.2K |
| Earning Date | 11-18-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.11 | N/A |
| Revenue Next Year | $104.97 | $392.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.35 |
| 52 Week High | $9.54 | $3.60 |
| Indicator | ICCM | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.69 | 44.96 |
| Support Level | $0.65 | $0.37 |
| Resistance Level | $0.74 | $1.15 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 18.43 | 61.17 |
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.